Hydrocortisone Panpharma (Hydrocortisone Sodium Succinate)

Hydrocortisone Panpharma is employed when a rapid systemic glucocorticoid effect is required.

• Acute adrenal crisis or primary/secondary adrenal insufficiency needing immediate cortisol replacement.
• Severe septic shock or systemic inflammatory response where rapid anti‑inflammatory action is indicated.
• Life‑threatening allergic reactions, including anaphylaxis, that require fast glucocorticoid support.
• Acute asthma or COPD exacerbations unresponsive to inhaled therapy.
• Exacerbations of rheumatic diseases such as rheumatoid arthritis or systemic lupus erythematosus.
• Post‑operative or trauma‑related inflammation where intravenous or intramuscular corticosteroid coverage is desired.

• Hydrocortisone sodium succinate is a water‑soluble ester of hydrocortisone that, after intramuscular or intravenous administration, is rapidly hydrolyzed to active hydrocortisone. The active molecule diffuses into cells and binds cytoplasmic glucocorticoid receptors, forming a hormone‑receptor complex that translocates to the nucleus. This complex interacts with glucocorticoid response elements on DNA, modulating transcription of anti‑inflammatory proteins and suppressing pro‑inflammatory cytokine production, thereby producing systemic glucocorticoid effects.

Adverse reactions to Hydrocortisone Panpharma can vary in frequency and severity.

Common

• Transient increase in blood glucose levels.
• Mild electrolyte disturbances such as sodium retention or potassium loss.
• Local irritation or pain at the injection site.
• Headache or dizziness.
• Gastrointestinal discomfort, including nausea or abdominal pain.
• Mood changes such as mild euphoria or irritability.
• Insomnia or sleep disturbances.

Serious

• Severe hyperglycemia or new‑onset diabetes mellitus.
• Significant hypertension or fluid overload.
• Acute adrenal suppression after abrupt discontinuation.
• Severe allergic reactions, including anaphylaxis.
• Opportunistic infections or reactivation of latent infections.
• Gastrointestinal bleeding or ulceration, especially with concomitant NSAIDs.
• Osteonecrosis or avascular necrosis of bone with prolonged high‑dose therapy.

When prescribing Hydrocortisone Panpharma, clinicians should consider several precautionary measures to minimize risks.

• Assess baseline blood glucose and electrolyte status before initiating therapy.
• Use the lowest effective dose for the shortest duration required.
• Monitor blood pressure and fluid balance, especially in patients with cardiac or renal disease.
• Evaluate for signs of infection; avoid use in uncontrolled systemic infections without appropriate antimicrobial coverage.
• Taper gradually after prolonged treatment to prevent adrenal insufficiency.
• Consider pregnancy and lactation status; weigh potential benefits against unknown fetal risks.
• Review patient history for hypersensitivity to corticosteroids or formulation excipients.

Hydrocortisone Panpharma may interact with other medicines, altering its efficacy or increasing toxicity.

Avoid

• Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) that may reduce corticosteroid levels.
• Simultaneous administration of systemic anticoagulants without monitoring, as glucocorticoids can enhance anticoagulant effect.
• Co‑administration with other systemic glucocorticoids, which can increase risk of adrenal suppression and side effects.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) – increased risk of gastrointestinal ulceration.
• Diuretics – may exacerbate electrolyte disturbances, especially hypokalemia.
• Antidiabetic agents – glucocorticoid‑induced hyperglycemia may require dose adjustment.
• Vaccines, particularly live attenuated – immunosuppression may diminish vaccine efficacy.